{"quote": {"result": [{"language": "en-US", "region": "US", "quoteType": "EQUITY", "typeDisp": "Equity", "quoteSourceName": "Delayed Quote", "triggerable": false, "customPriceAlertConfidence": "LOW", "currency": "ILA", "esgPopulated": false, "market": "il_market", "longName": "Compugen Ltd.", "marketState": "CLOSED", "regularMarketPrice": 280.0, "messageBoardId": "finmb_166115", "exchange": "TLV", "shortName": "COMPUGEN", "exchangeTimezoneShortName": "IDT", "exchangeTimezoneName": "Asia/Jerusalem", "regularMarketChangePercent": 8.149867, "gmtOffSetMilliseconds": 10800000, "fiftyTwoWeekLowChange": 70.600006, "fiftyTwoWeekLowChangePercent": 0.33715382, "fiftyTwoWeekRange": "209.4 - 799.0", "fiftyTwoWeekHighChange": -519.0, "fiftyTwoWeekHighChangePercent": -0.64956194, "fiftyTwoWeekLow": 209.4, "fiftyTwoWeekHigh": 799.0, "earningsTimestamp": 1541596500, "earningsTimestampStart": 1541596500, "earningsTimestampEnd": 1541596500, "trailingAnnualDividendRate": 0.0, "trailingAnnualDividendYield": 0.0, "epsTrailingTwelveMonths": -1.53, "epsForward": -0.71, "epsCurrentYear": -0.54, "firstTradeDateMilliseconds": 1029133800000, "priceHint": 2, "regularMarketChange": 21.100006, "regularMarketTime": 1683815054, "regularMarketDayHigh": 282.8, "regularMarketDayRange": "269.0 - 282.8", "regularMarketDayLow": 269.0, "regularMarketVolume": 221465, "regularMarketPreviousClose": 258.9, "bid": 259.9, "ask": 260.0, "fullExchangeName": "Tel Aviv", "financialCurrency": "USD", "regularMarketOpen": 269.0, "averageDailyVolume3Month": 130665, "averageDailyVolume10Day": 115386, "priceEpsCurrentYear": -518.5185, "sharesOutstanding": 86624600, "bookValue": 0.897, "fiftyDayAverage": 253.178, "fiftyDayAverageChange": 26.822006, "fiftyDayAverageChangePercent": 0.1059413, "twoHundredDayAverage": 327.9725, "twoHundredDayAverageChange": -47.972504, "twoHundredDayAverageChangePercent": -0.14626989, "marketCap": 242548880, "forwardPE": -3.9436622, "priceToBook": 312.1516, "sourceInterval": 15, "exchangeDataDelayedBy": 15, "tradeable": false, "cryptoTradeable": false, "symbol": "CGEN.TA"}], "error": null}, "summary": {"result": [{"assetProfile": {"address1": "Azrieli Center", "address2": "Building D 26 Harokmim Street", "city": "Holon", "zip": "5885849", "country": "Israel", "phone": "972 3 765 8585", "fax": "972 3 765 8555", "website": "https://cgen.com", "industry": "Biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "longBusinessSummary": "Compugen Ltd., a clinical-stage therapeutic discovery and development company, researches, develops, and commercializes therapeutic and product candidates in Israel, the United States, and Europe. The company's immuno-oncology pipeline consists of COM701, an anti-PVRIG antibody that is in Phase I clinical study used for the treatment of solid tumors; COM902, a therapeutic antibody targeting TIGIT, which is in Phase I monotherapy clinical study in patients with advanced malignancies through sequential dose escalations; Bapotulimab, a therapeutic antibody targeting ILDR2 that is in Phase I clinical study in patients with na\u00efve head and neck squamous cell carcinoma; and Rilvegostomig, a novel anti-TIGIT/PD-1 bispecific antibody, which is in Phase II clinical study in patients with advanced or metastatic non-small cell lung cancer. Its therapeutic pipeline also includes early-stage immuno-oncology programs focused to address various mechanisms of immune resistance; and COM503, high affinity antibody, which blocks the interaction between IL-18 binding protein and IL-18. The company has collaboration agreement with Bayer Pharma AG for the research, development, and commercialization of antibody-based therapeutics against the company's immune checkpoint regulators; Bristol-Myers Squibb to evaluate the safety and tolerability of COM701 in combination with Bristol-Myers Squibb's PD-1 immune checkpoint inhibitor Opdivo in patients with advanced solid tumors; and Johns Hopkins School of Medicine to evaluate novel T cell and myeloid checkpoint targets. It has license agreement with AstraZeneca for the development of bi-specific and multi-specific immuno-oncology antibody products; and research collaboration with Johns Hopkins University for myeloid. Compugen Ltd. was incorporated in 1993 and is headquartered in Holon, Israel.", "fullTimeEmployees": 69, "companyOfficers": [{"maxAge": 1, "name": "Dr. Anat  Cohen-Dayag Ph.D.", "age": 55, "title": "CEO, Pres & Director", "yearBorn": 1967, "fiscalYear": 2022, "totalPay": {"raw": 796519, "fmt": "796.52k", "longFmt": "796,519"}, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Dr. Zurit  Levine Ph.D.", "age": 54, "title": "Sr. VP of Technology Innovation", "yearBorn": 1968, "fiscalYear": 2022, "totalPay": {"raw": 345697, "fmt": "345.7k", "longFmt": "345,697"}, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Dr. Henry  Adewoye M.D.", "age": 57, "title": "Sr. VP & Chief Medical Officer", "yearBorn": 1965, "fiscalYear": 2022, "totalPay": {"raw": 605291, "fmt": "605.29k", "longFmt": "605,291"}, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Mr. Alberto  Sessa", "age": 60, "title": "Chief Financial Officer", "yearBorn": 1962, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Ms. Yvonne  Naughton", "title": "Head of Investor Relations & Corp. Communications", "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Mr. Eran Ben Dor", "title": "Gen. Counsel & Corp. Sec.", "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Ms. Dorit  Amitay", "age": 54, "title": "VP of HR", "yearBorn": 1968, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Dr. Yaron  Turpaz M.B.A., Ph.D., MBA", "age": 51, "title": "Sr. VP & Sr. Advisor of Computational Discovery", "yearBorn": 1971, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Rivka  Schwartz", "title": "VP Research and Discovery", "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Dr. Eran  Ophir Ph.D.", "age": 44, "title": "Sr. VP of Research & Drug Discovery", "yearBorn": 1978, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}], "compensationAsOfEpochDate": 1672444800, "maxAge": 86400}}], "error": null}}